Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-14 |
2024-03 |
-0.26 |
-0.34 |
-0.08 |
-30.77% |
2024-03-29 |
2023-12 |
-0.42 |
-0.23 |
0.19 |
45.24% |
2024-03-29 |
2023-12 |
-0.42 |
N/A |
N/A |
N/A |
2023-11-14 |
2023-09 |
-0.49 |
-0.46 |
0.03 |
6.12% |
2023-11-14 |
2023-09 |
-0.49 |
N/A |
N/A |
N/A |
2023-08-07 |
2023-06 |
-0.65 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-06 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2022-11-16 |
Chardan Capital |
Upgrade |
|
Buy |
2022-08-11 |
SVB Leerink |
Upgrade |
|
Outperform |
2022-06-07 |
Cantor Fitzgerald |
Upgrade |
|
Overweight |
2022-06-06 |
B. Riley Securities |
Upgrade |
|
Buy |
2022-06-06 |
Chardan Capital |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2022-06-08 |
BUSHNELL LAURA I |
Director |
19.20K |
Purchase |
2020-12-22 |
DRUKER BRIAN J |
Director |
54.81K |
Stock Award(Grant) |
2023-08-09 |
HAMDY AHMED |
President |
0.00 |
Purchase |
2021-12-22 |
HWANG SOOIN |
Officer |
390.49K |
Purchase |
2023-08-09 |
IZUMI RAQUEL E. |
President |
0.00 |
Purchase |
2021-06-28 |
LEE JOHN H. |
Director |
799.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Goldman Sachs Group Inc |
2.06M |
2.68M |
9.65% |
2023-06-29 |
Sage Rhino Capital LLC |
1.69M |
2.19M |
7.89% |
2023-06-29 |
Affinity Asset Advisors, Llc |
1.49M |
1.94M |
6.98% |
2023-06-29 |
Long Focus Capital Management, LLC |
1.10M |
1.43M |
5.14% |
2023-06-29 |
Rock Springs Capital Management, LP |
891.72K |
1.16M |
4.17% |
2023-06-29 |
Citadel Advisors Llc |
660.52K |
858.68K |
3.09% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
334.11K |
434.34K |
1.56% |
2023-06-29 |
Vanguard Extended Market Index Fund |
173.35K |
225.36K |
0.81% |
2023-05-30 |
Fidelity Extended Market Index Fund |
74.08K |
137.06K |
0.35% |
2023-05-30 |
Fidelity Total Market Index Fund |
27.46K |
50.79K |
0.13% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
16.23K |
30.02K |
0.08% |
2023-05-30 |
Fidelity NASDAQ Composite Index Fund |
9.30K |
17.20K |
0.04% |